How Much Did 64x Bio Raise?
Funding & Key Investors

64x Bio has secured a significant enterprise-level funding round, with the total capital raised standing at $55M. The company recently announced a major strategic investment of $55M, underscoring its pivotal role in advancing cell line engineering and therapeutic system design. This latest financing round is expected to accelerate 64x Bio's mission to provide end-to-end platforms for scalable therapeutic development.

What is 64x Bio?

64x Bio
Business ServicesResearch & Development

64x Bio is a pioneering biotechnology firm specializing in cell line engineering. The company offers a comprehensive, end-to-end platform designed for the creation of scalable therapeutic systems. Its innovative solutions are tailored to assist clients in developing advanced therapeutic methods, thereby supporting the biotechnology and pharmaceutical sectors in enhancing their product pipelines. 64x Bio is committed to driving progress in biomanufacturing through the application of cutting-edge technologies.

How much funding has 64x Bio raised?

64x Bio has raised a total of $55M across 1 funding round:

2022

Series A

$55M

Series A (2022): $55M with participation from Northpond Ventures and Lifeforce Capital Gp I

Key Investors in 64x Bio

Northpond Ventures

Northpond Ventures is a venture capital firm that typically invests in companies at the forefront of scientific innovation. Their focus often includes life sciences and technology sectors, suggesting a strategic interest in 64x Bio's advanced cell line engineering.

Lifeforce Capital Gp I

Lifeforce Capital is a venture capital firm established in 2015, specializing in identifying and scaling software-driven companies within the healthcare industry. Their investment in 64x Bio indicates a belief in the company's technological approach to therapeutic development.

What's next for 64x Bio?

With the recent infusion of capital, 64x Bio is poised for significant expansion and further innovation in its cell line engineering platform. The major strategic investment signals strong confidence from backers in the company's potential to revolutionize therapeutic development. This backing will likely fuel advancements in research and development, enabling 64x Bio to scale its operations and broaden its market reach. The company's focus on creating scalable therapeutic systems positions it as a key player in addressing critical needs within the biopharmaceutical industry, potentially leading to accelerated drug development timelines and improved manufacturing efficiencies.

See full 64x Bio company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Business ServicesResearch & DevelopmentSoftware TestingMobile App DevelopmentSoftware
Business ServicesHuman Resources Management Systems (HRMS)
Business ServicesSoftware TestingConsumer ServicesRepair Services
Business ServicesHuman Resources Management Systems (HRMS)Mobile App DevelopmentSoftwareHuman Resources SoftwareProject Management

Frequently Asked Questions Regarding 64x Bio Financial Insights

What are the most recent funding rounds that 64x Bio has completed, and what were the funding rounds?
64x Bio has recently completed 1 funding rounds: Series A on Jan 19, 2022.
What is the total amount of funding 64x Bio has raised to date?
64x Bio has raised a total of $55M in funding to date.
How many funding rounds has 64x Bio completed?
64x Bio has completed 1 funding rounds.
How much funding did 64x Bio raise in its most recent funding round?
64x Bio raised $55M in its most recent funding round.
Who are the lead investors in 64x Bio's latest funding round?
The lead investor in 64x Bio's latest funding round was Northpond Ventures. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in 64x Bio's history?
The largest funding round in 64x Bio's history was $55M.
See more information about 64x Bio